We’re All The Poorer for Shareholders’ Loss of Nerve on Executive Pay
Investors failed another test of backbone last week, as a number of eye-popping pay packages overcame the threat of voter rebellions at annual general meetings. The board of AstraZeneca asked shareholders to support their decision to award the chief executive, Pascal Soriot, £18m in annual pay and perks...
Login to comment.